Literature DB >> 8060810

Myocardial function and postmortem myocardial histology in children given anthracycline therapy for cancer.

J Pihkala1, H Sariola, U M Saarinen.   

Abstract

In an autopsy series of children with cancer, histopathologic myocardial changes caused by anthracyclines (A) were evaluated. The series comprised three groups: group A, 9 patients given A whose myocardial function had been evaluated before death; group B, 10 patients given A, but no lifetime echocardiographic evaluation; group C, 8 patients treated with chemotherapy regimens not including A. Both the cumulative A dose (P < 0.01) and the age of the patient at death (P < 0.001) were correlated with the pathologic changes in the myocardium. In echocardiography of group A patients, left ventricular (LV) contractility was subnormal in 5 (56%) patients, and the afterload was elevated in 3 (33%); the morphologic changes correlated with the LV wall stress (= afterload) (P < 0.05) and with LV fractional shortening (P < 0.04). We conclude that clinical decisions about A therapy should be based on cumulative A dose and myocardial function tests. Myocardial biopsies should be restricted to selected cases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8060810     DOI: 10.3109/08880019409141669

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  2 in total

1.  Doxorubicin-heparin complex: reduction of cardiotoxicity of doxorubicin.

Authors:  Y Mizuno; T Hara; S Tachibana; K Uragoh; K Akazawa; K Ueda
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  Tissue and flow myocardial performance index measurements taken during dobutamine stress echocardiography for early diagnosis of late anthracycline cardiotoxicity.

Authors:  Ayşe Yildirim; F Sedef Tunaoğlu; F Güçlü Pinarli; Mustafa Ilhan; Aynur Oğuz; Ceyda Karadeniz; Rana Olguntürk; Deniz Oğuz; Serdar Kula
Journal:  Pediatr Cardiol       Date:  2009-11-24       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.